

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	09/997,003	11/30/2001	Craig A. Rosen	PA003P1	7261
	22195 7	7590 12/19/2003		EXAMINER	
	HUMAN GENOME SCIENCES INC 9410 KEY WEST AVENUE			CHAKRABARTI, ARUN K	
	ROCKVILLE,		ART UNIT	PAPER NUMBER	
			1634		
			DATE MAIL ED: 12/10/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. **09/997,003**

Applicant(s)

Rosen

Examiner

Arun Chakrabarti

Art Unit 1634



The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
	for Reply							
THE	A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.							
	sions of time may be available under the provisions of 37 CFR 1.136 (a), li g date of this communication.	in no event, however, ma	ay e reply h	be timely filed after SIX (6) MONTHS from the				
- If the property - If NO property - If	- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely If NO period for reply is specified above, the meximum statutory period will expire SIX (6) MONTHS from the mailing date of this communication Feilure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133) Any reply received by the Office later than three months efter the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status								
1) 💢	Responsive to communication(s) filed on <u>Nov 20,</u>			•				
2a) ∐		ction is non-final.						
3)□	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213.							
-	tion of Claims							
4) [X]	Claim(s) 2 and 25-40			is/are pending in the application.				
4	a) Of the above, claim(s)			is/are withdrawn from consideration.				
5) 🗆	Claim(s)			is/are allowed.				
6) 🗶	Claim(s) 2 and 25-40			is/are rejected.				
7) 🗆	Claim(s)			is/are objected to.				
8) 🗌	Claims	are	subject	to restriction and/or election requirement.				
	tion Papers							
9) 🗌	The specification is objected to by the Examiner.							
10)	The drawing(s) filed on is/are	e a) 🗌 accepted	lor b∫	\sqsupset objected to by the Examiner.				
	Applicant may not request that any objection to the o							
11)	The proposed drawing correction filed on	is:	a) 🗌 a	pproved b) \square disapproved by the Examiner.				
	If approved, corrected drawings are required in reply							
12)	The oath or declaration is objected to by the Exam	riner.						
_	under 35 U.S.C. §§ 119 and 120							
	Acknowledgement is made of a claim for foreign p	priority under 35	U.S.C.	§ 119(a)-(d) or (f).				
a)	All b)□ Some* c)□ None of:							
1	1. \square Certified copies of the priority documents hav							
	2. \square Certified copies of the priority documents hav							
	3. Copies of the certified copies of the priority dapplication from the International Bure	eau (PCT Rule 17	7.2(a)).					
	ee the attached detailed Office action for a list of th	ne certified copies	s not re					
	Acknowledgement is made of a claim for domestic							
a) 🗆				·				
	Acknowledgement is made of a claim for domestic	priority under 3!	5 U.S.C	2. §§ 120 and/or 121.				
Attachme								
	ice of References Cited (PTO-892)			-413) Paper No(s)				
	ice of Draftsperson's Petent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Peper No(s), 1003	5) Notice of Inform						
3) [X] IIIV	3) X Information Disclosure Statement(s) (PTO-1449) Peper No(s). 1003 6) Detailed Action							

Application/Control Number: 09/997,003 Page 2

Art Unit: 1634

DETAILED ACTION

Election/Restriction

1. Applicant's election with traverse of Group II in Paper No. 1103 is acknowledged.

Applicant has canceled claims 1 and 3-24 without prejudice or disclaimer and added new claims 25-40. The traversal is on the ground(s) that the examination of claims of Groups I and III-VI would pose no undue burden. Argument regarding examination of claims of all other groups are moot in view of the amendment. However, claim 2 belonging to Group I is still pending. This claim is also hereby being examined.

Claim Rejections - 35 USC § 112

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claim 2 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claim 2 is rejected because it is dependent on a canceled and therefore non-existent claim 1. In absence of claim 1, it is not clear what nucleic acid molecule is claimed in claim 2. The metes and bounds of the claims are vague and indefinite.

4. The following is a quotation of the first paragraph of 35 U.S.C. 112:

Application/Control Number: 09/997,003 Page 3

Art Unit: 1634

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 25-40 are rejected under 35 U.S.C. 112, first paragraph, as based on a disclosure which is not enabling. The SEQ ID NO; or the exact nucleotide sequence of HTELE03 cDNA contained in ATCC deposit No. PTA-498 critical or essential to the practice of the invention, but not included in the claim(s) is not enabled by the disclosure. See *In re Mayhew*, 527 F.2d 1229, 188 USPQ 356 (CCPA 1976). Although no prior art discloses amino acid residues 1 to 63 of SEQ ID NO: 41 and has been found unique, it is not disclosed whether nucleotide sequence of HTELE03 cDNA contained in ATCC deposit No. PTA-498 is identical to the sequence encoding amino acid residues 1 to 63 of SEQ ID NO: 41 or if it is different, what is the percent of similarity. ATCC deposit No. PTA-498 is not a database and therefore was unsearchable. In absence of a SEQ ID Number or Genbak Accession Number for ATCC deposit No. PTA-498, claims 25-40 do not comply with sequence rule of USPTO. Moreover, this is improper incorporation by reference, as the essential elements of the claimed invention i.e., the exact nucleotide sequence of HTELE03 cDNA contained in ATCC deposit No. PTA-498 is not disclosed either in the claim or in the specification.

Conclusion

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Arun Chakrabarti, Ph.D., whose telephone number is (703)

Art Unit: 1634

306-5818. This phone number will be changed to (571)272-0740 on and from January 14, 2004. The examiner can normally be reached on 7:00 AM-4:30 PM from Monday to Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (703) 308-1119. The fax phone number for this Group is (703) 746-4979. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group LIE Chantae Dessau whose telephone number is (703) 605-1237.

ARUNK. CHAKRABART PATENT EXAMINER Arun Chakrabarti,

Patent Examiner,

December 2, 2003

CARY BENZION, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1888